Claims for Patent: 7,833,521
✉ Email this page to a colleague
Summary for Patent: 7,833,521
Title: | Methods of treating using hormone-albumin fusion proteins |
Abstract: | Biologically active polypeptides comprising a therapeutically active polypeptide fused to human serum albumin or a variant of human serum albumin, methods for preparation, nucleotide sequences encoding such fusion polypeptides, expression cassettes comprising such nucleotide sequences, self-replicating plasmids containing such expression cassettes, and pharmaceutical compositions containing fusion polypeptides. |
Inventor(s): | Fleer; Reinhard (Bure-sur-Yvette, FR), Fournier; Alain (Chaenay-Malabry, FR), Guitton; Jean-Dominique (Paris, FR), Jung; Gerard (Montlhery, FR), Yeh; Patrice (Paris, FR) |
Assignee: | Novozymes Biopharma DK A/S (Bagsvaerd, DK) |
Application Number: | 11/927,628 |
Patent Claims: | 1. A method of treating a patient in need of a hormone, comprising the step of administering to said patient a fusion protein comprising hormone and albumin or an
albumin variant, wherein (i) said fusion protein has a higher plasma stability than the unfused hormone, (ii) said albumin or albumin variant is located either at the N-terminus or C-terminus of said fusion protein, and (iii) said fusion protein retains
the therapeutic activity of the unfused hormone.
2. The method of claim 1, wherein said fusion protein comprises albumin. 3. The method of claim 1, wherein said fusion protein comprises an albumin variant. 4. The method of claim 3, wherein said albumin variant is a fragment of albumin. 5. The method of claim 3, wherein said albumin variant has a mutation of one or more residues. 6. The method of claim 3, wherein said albumin variant has a deletion of one or more residues. 7. The method of claim 3, wherein said albumin variant has a mutation and a deletion of one or more residues. 8. The method of claim 3, wherein said albumin variant has an addition of one or more residues. 9. The method of claim 1, wherein said fusion protein comprises an N-terminal methionine. 10. The method of claim 1, wherein said fusion protein comprises a peptide linker. 11. The method of claim 1, wherein said hormone is fused to the N-terminal end of said albumin or albumin variant. 12. The method of claim 1, wherein said hormone is fused to the C-terminal end of said albumin or albumin variant. 13. A method of treating a patient in need of a hormone, comprising the step of administering to said patient a fusion protein comprising hormone and a mature form of albumin, wherein (i) said fusion protein has a higher plasma stability than the unfused hormone, (ii) said mature form of albumin is located either at the N-terminus or C-terminus of said fusion protein, and (iii) said fusion protein retains the therapeutic activity of the unfused hormone. 14. The method of claim 13, wherein said fusion protein comprises an N-terminal methionine. 15. The method of claim 13, wherein said fusion protein comprises a peptide linker. 16. The method of claim 13, wherein said hormone is fused to the N-terminal end of said mature form of albumin. 17. The method of claim 16, wherein said fusion protein comprises an N-terminal methionine. 18. The method of claim 16, wherein said fusion protein comprises a peptide linker. 19. The method of claim 13, wherein said hormone is fused to the C-terminal end of said mature form of albumin. 20. The method of claim 19, wherein said fusion protein comprises an N-terminal methionine. 21. The method of claim 19, wherein said fusion protein comprises a peptide linker. 22. The method of claim 1, wherein said hormone is human hormone, and said albumin or an albumin variant is human albumin or a human albumin variant. 23. The method of claim 13, wherein said hormone is human hormone, and said mature form of albumin is mature form of human albumin. |
Details for Patent 7,833,521
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
---|---|---|---|---|---|---|---|
Grifols Therapeutics Llc | ALBUKED, PLASBUMIN-20, PLASBUMIN-25, PLASBUMIN-5 | albumin (human) | For Injection | 101138 | 10/21/1942 | ⤷ Try a Trial | 2012-01-31 |
Baxalta Us Inc. | BUMINATE, FLEXBUMIN | albumin (human) | Injection | 101452 | 03/03/1954 | ⤷ Try a Trial | 2012-01-31 |
Csl Behring Ag | ALBURX | albumin (human) | Injection | 102366 | 07/23/1976 | ⤷ Try a Trial | 2012-01-31 |
Grifols Biologicals Llc | ALBUTEIN | albumin (human) | Injection | 102478 | 08/15/1978 | ⤷ Try a Trial | 2012-01-31 |
Instituto Grifols, S.a. | HUMAN ALBUMIN GRIFOLS | albumin (human) | Injection | 103352 | 02/17/1995 | ⤷ Try a Trial | 2012-01-31 |
Instituto Grifols, S.a. | HUMAN ALBUMIN GRIFOLS | albumin (human) | Injection | 103352 | 06/11/2003 | ⤷ Try a Trial | 2012-01-31 |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.